Podcast: BMS and Bird & Bird on doing major deals in a pandemic

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Podcast: BMS and Bird & Bird on doing major deals in a pandemic

Sponsored by

twobirds-400px.jpg
 L to R: Henry Hadad, James Baillieu, Sally Shorthose

Max Walters joins Sally Shorthose and James Baillieu of Bird & Bird and Henry Hadad of Bristol Myers Squibb to discuss how COVID-19 has shaped transactional work

In the last 10 months, we have all become accustomed to working remotely and doing things differently. For lawyers, one of the impacts has been on major deals, particularly those with a cross-jurisdictional focus.

In Managing IP’s latest podcast, panellists from Bristol Myers Squibb and Bird & Bird share their thoughts on whether efficiency has increased, if we have said goodbye to paper for good, and whether we are in a licensor or licensee market. 

To learn more about completing deals in a pandemic, and for a preview of the year ahead, check out our 40-minute podcast by clicking on the link above.

more from across site and SHARED ros bottom lb

More from across our site

The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Gift this article